Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras signaling pathway

International Journal of Cancer

Volumn 65, Issue 2, 1996, Pages 186-191

  Clark, Jeffrey W ^a,c   Santos Moore, Anabela ^a   Stevenson, Lisa E ^b   Raymond Frackelton Jr , A ^a,b  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENISTEIN; HERBIMYCIN A; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BENZOQUINONES; BREAST NEOPLASMS; CELL DIVISION; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; FEMALE; GENISTEIN; GRB2 ADAPTOR PROTEIN; HUMANS; ISOFLAVONES; LACTAMS, MACROCYCLIC; PROTEIN-TYROSINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); QUINONES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0030071724     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960117)65:2<186::AID-IJC10>3.0.CO;2-C     Document Type: Article

References (21)

1. AKIYAMA, Y. and OGAWARA, H., Use and specificity of genistein as inhibitor of protein-tyrosine kinases. Methods Enzymol., 201, 362-370 (1991).
2. BARNES, D.M., c-erbB-2 amplification in mammary carcinoma. J. Cell. Biochem., Suppl, 17G, 132-138 (1993).
3. BOYLAN, J.M. and GRUPPUSO, P.A., In vitro and in vivo regulation of hepatic mitogen-activated protein kinases in fetal rats. Amer. J. Physiol., 267, G1078-G1086 (1994).
4. CANO, E. and MAHADEVAN, L.C., Parallel signal processing among mammalian MAPKs, TIBS, 20, 117-122 (1995).
5. ras upon T-cell activation. Nature (Lond.), 346, 719-723 (1990).
6. EDELMANN, L.A., SANTOS-MOORE, A., CLARK, J.W. and FRACKELTON, A.R., JR., Modulation of Shc tyrosine phosphorylation in breast cancer cell lines [Abstract]. Proc. Amer. Ass. Cancer Res., 35, 2666 (1994).
7. ENNIS, B.W., LIPPMAN, M.E. and DICKSON, R.B., The EGF receptor system as a target for antitumor therapy. Cancer Invest., 9, 553-562 (1991).
8. FAALAND, C.A., MERMELSTEIN, F.H., HAYASHI, J. and LASKIN, J.D., Rapid uptake of tyrphostin into A431 human epidermoid cells is followed by delayed inhibition of epidermal growth factor (EGF)-stimulated EGF receptor tyrosine kinase activity. Mol. cell. Biol., 11, 2697-2703 (1991).
9. FRY, D.W., KRAKER, A.J., MCMICHAEL, A., AMBROSO, L.A., NELSON, J.M., LEOPOLD, W.R., CONNORS, R.W. and BRIDGES, A.J., A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science, 265, 1093-1095 (1994).
10. HONMA, Y., OKABE-KADO, J., KASUKABE, T., HOZUMI, M., KODAMA, H., KAJIGAYA, S., SUDA, T. and MIURA, Y., Herbimycin A, an inhibitor of tyrosine kinase, prolongs survival of mice inoculated with myeloid leukemia C1 cells and high expression of v-abl tyrosine kinase. Cancer Res., 52, 4017-4020 (1992).
11. KLIJN, J.G., BERNS, P.M., SCHMITZ, P.I. and FOEKENS, J.A., The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review of 5232 patients. Endocr. Rev., 13, 3-17 (1992).
12. LICKUN, F.M., EVANS, W.E., FORSYTH, C.J., WADDICK, K.G., T-AHLGREN, L., CHELSTROM, L.M., BURKHARDT, A., BOLEN, J. and MYERS, D.E., Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science, 267, 886-891 (1995).
13. c-src with two major signaling pathways in human breast cancer. Proc. nat. Acad. Sci. (Wash.), 91, 83-87 (1994).
14. MONTI, E. and SINHA, B.K., Antiproliferative effect of genistein and adriamycin against estrogen-dependent and -independent human breast carcinoma cell lines. Anticancer Res., 14, 1221-1226 (1994).
15. MURAKAMI, Y., MIZUNO, S. and UEHARA, Y., Accelerated degredation of 160 kDa epidermal growth factor (EGF) receptor precursor by the tyrosine kinase inhibitor herbimycin A in the endoplasmic reticulum of A431 human epidermoid carcinoma cells. Biochem. J., 301, 63-68 (1994).
16. REDDY, K.B., MANGOLD, G.L., TANDON, A.K., YONEDA, T., MUNDY, G.R., ZILBERSTEIN, A. and OSBORNE, C.K., Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res., 52, 3636-3641 (1992).
17. ROZAKIS-ADCOCK, M., MCGLADE, J., MBAMALU, G., PELICCI, G., DALY, R., LI, W., BATZER, A., THOMAS, S., BRUGGE, J., PELICCI, P.G., SCHLESSINGER, J. and PAWSON, T., Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature (Lond.), 360, 689-692 (1992).
18. SARUP, J.C., JOHNSON, R.M., KING, K.L., FENDLY, B.M., LIPARI, M.T., NAPIER, M.A., ULLRICH, A. and SHEPARD, H.M., Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul., 1, 72-82 (1991).
19. SCHLESSINGER, J., How receptor tyrosine kinases activate Ras. TIBS, 18, 273-275 (1993).
20. SEGATTO, O., PELICCI, G., GIULI, S., DIGIESI, G., DIFIORE, P.P., MCGLADE, J., PAWSON, T. and PELICCI, P.G., Shc products are substrates of erbB-2 kinase. Oncogene, 8, 2105-2112 (1993).
21. UEHARA, Y. and FUKAZAWA, H., Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinases. Methods Enzymol., 201, 370-379 (1991).